Underdiagnosis and prognosis of chronic obstructive pulmonary disease after percutaneous coronary intervention: A prospective study

International Journal of COPD

Volumn 10, Issue , 2015, Pages 1353-1361

  Almagro, Pere ^a   Lapuente, Anna ^b   Pareja, Julia ^a   Yun, Sergi ^a   Garcia, Maria Estela ^c   Padilla, Ferrán ^b   Heredia, Josep Ll ^b   Sierra, Alex De La ^a   Soriano, Joan B ^d  

^a Department of Internal Medicine ^*  (Spain)

^b HOSPITAL MÚTUA DE TERRASSA   (Spain)

^c Sant Joan Despi   (Spain)

^d UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

Ischemic heart disease; Mortality; Myocardial infarction; Prognosis

Indexed keywords

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHARLSON COMORBIDITY INDEX; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; CONTROLLED STUDY; CORONARY BLOOD VESSEL; DYSLIPIDEMIA; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PREVALENCE; PROGNOSIS; PROSPECTIVE STUDY; RISK FACTOR; SPIROMETRY; VALVULAR HEART DISEASE; ADVERSE EFFECTS; CORONARY ARTERY DISEASE; EPIDEMIOLOGY; KAPLAN MEIER METHOD; LUNG; MIDDLE AGED; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK ASSESSMENT; SPAIN; TIME FACTOR; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; COMORBIDITY; CORONARY ARTERY DISEASE; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG; MALE; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; PREDICTIVE VALUE OF TESTS; PREVALENCE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK ASSESSMENT; RISK FACTORS; SPAIN; SPIROMETRY; TIME FACTORS; TREATMENT OUTCOME;

EID: 84937604786     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S84482     Document Type: Article

References (48)

1. GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385(9963):117-171.
2. Soriano JB, Almagro P, Sauleda Roig J. Causes of mortality in COPD. Arch Bronconeumol. 2009;45(Suppl 4):8-13.
3. Berger JS, Sanborn TA, Sherman W, et al. Effect COPD on survival of patients with coronary heart disease having percutaneous coronary intervention. Am J Cardiol. 2004;94(5):649-651.
4. Selvaraj CL, Gurm HS, Gupta R, et al. COPD as a predictor of mortality in patients undergoing percutaneous coronary intervention. Am J Cardiol. 2005;96(6):756-759.
5. Enriquez JR, Parikh SV, Selzer F, et al. Increased adverse events after percutaneous coronary intervention in patients with COPD: insights from the National Heart, Lung and Blood Institute dynamic registry. Chest. 2011;140(3):604-610.
6. Hawkins NM, Huang Z, Pieper KS, et al. COPD is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). Eur J Heart Fail. 2009;11(3):292-298.
7. Hadi HA, Zubaid M, Al Mahmeed W, et al. Prevalence and prognosis of COPD among 8167 Middle Eastern patients with acute coronary syndrome. Clin Cardiol. 2010;33(4):228-235.
8. Wakabayashi K, Gonzalez MA, Delhaye C, et al. Impact of COPD on acute-phase outcome of myocardial infarction. Am J Cardiol. 2010;106(3):305-309.
9. Campo G, Guastaroba P, Marzocchi A, et al. Impact of COPD on long-term outcome after ST-segment elevation myocardial infarction receiving primary percutaneous coronary intervention. Chest. 2013;144(3):750-757.
10. Bursi F, Vassallo R, Weston SA, Killian JM, Roger VL. COPD after myocardial infarction in the community. Am Heart J. 2010;160(1): 95-101.
11. Konecny T, Somers K, Orban M, et al. Interactions between COPD and outcomes after percutaneous coronary intervention. Chest. 2010; 138(3):621-627.
12. Zhang JW, Zhou YJ, Yang Q, Yang SW, Nie B, Xu XH. Impact of COPD on outcomes and hospital days after percutaneous coronary intervention. Angiology. 2013;64(6):430-434.
13. Miravitlles M, Soriano JB, García-Río F, et al. Prevalence of COPD in Spain: impact of undiagnosed COPD on quality of life and daily life activities. Thorax. 2009;64(10):863-868.
14. Llordés M, Jaén A, Almagro P, et al. Prevalence, risk factors and diagnostic accuracy of COPD among smokers in primary care. COPD. Epub 2014 Dec 4.
15. Soriano JB, Rigo F, Guerrero D, et al. High prevalence of undiagnosed airflow limitation in patients with cardiovascular disease. Chest. 2010; 137(2):333-340.
16. Roques F, Michel P, Goldstone AR, Nashef SA. The logistic Euro-SCORE. Eur Heart J. 2003;24(9):881-882.
17. Coluccia V, Burzotta F, Romagnoli E, et al. EuroSCORE predicts long-term mortality of unselected patients undergoing percutaneous coronary interventions. Int J Cardiol. 2013;167(4):1232-1236.
18. Fox KA, Eagle KA, Gore JM, Steg PG, Anderson FA; GRACE and GRACE2 Investigators. The Global Registry of Acute Coronary Events, 1999 to 2009 - GRACE. Heart. 2010;96(14):1095-1101.
19. Sianos G, Morel MA, Kappetein AP, et al. The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease. EuroIntervention. 2005;1(2):219-227.
20. Farooq V, Brugaletta S, Serruys PW. Contemporary and evolving risk scoring algorithms for percutaneous coronary intervention. Heart. 2011; 97(23):1902-1913.
21. Khattab AA, Hamm CW, Senges J, et al. Prognostic value of the modified American College of Cardiology/American Heart Association lesion morphology classification for clinical outcome after sirolimus-eluting stent placement (results of the prospective multicenter German Cypher Registry). Am J Cardiol. 2008;101(4):477-482.
22. Miller MR, Hankinson J, Brusasco V, et al; ATS/ERS Task Force. Standardisation of spirometry. Eur Respir J. 2005;26(2):319-338.
23. Ferris BG. Epidemiology standardization project (AmericanThoracic Society). Am Rev Respir Dis. 1978;118(6 pt 2)(Suppl 1):1-120.
24. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-383.
25. Vestbo J, Hurd SS, Agustí AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013; 187(4):347-365.
26. Vanfleteren LE, Spruit MA, Groenen M, et al. Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013;187(7):728-735.
27. Curkendall SM, DeLuise C, Jones JK, et al. Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients. Ann Epidemiol. 2006; 16(1):63-70.
28. Finkelstein J, Cha E, Scharf SM. Chronic obstructive pulmonary disease as an independent risk factor for cardiovascular morbidity. Int J Chron Obstruct Pulmon Dis. 2009;4:337-349.
29. Almagro P, Cabrera FJ, Diez J, et al. Comorbidities and short-term prognosis in patients hospitalized for acute exacerbation of COPD: the EPOC en servicios de medicina interna (ESMI) study. Chest. 2012; 142(5):1126-1133.
30. Müllerova H, Agusti A, Erqou S, Mapel DW. Cardiovascular comorbidity in COPD: systematic literature review. Chest. 2013;144(4):1163-1178.
31. Bérard E, Bongard V, Roche N, et al. Undiagnosed airflow limitation in patients at cardiovascular risk. Arch Cardiovasc Dis. 2011;104(12):619-626.
32. Yin L, Lensmar C, Ingelsson E, Bäck M. Differential association of chronic obstructive pulmonary disease with myocardial infarction and ischemic stroke in a nation-wide cohort. Int J Cardiol. 2014; 173(3):601-603.
33. Mooe T, Stenfors N. The prevalence of COPD in individuals with acute coronary syndrome: a spirometry-based screening study. COPD. Epub 2014 Nov 21.
34. Maddox TM, Stanislawski MA, Grunwald GK, et al. Nonobstructive coronary artery disease and risk of myocardial infarction. JAMA. 2014;312(17):1754-1763.
35. Wald DS, Morris JK, Wald NJ, et al. Randomized trial of preventive angioplasty in myocardial infarction. N Engl J Med. 2013;369(12):1115-1123.
36. Andell P, Koul S, Martinsson A, et al. Impact of chronic obstructive pulmonary disease on morbidity and mortality after myocardial infarction. Open Heart. 2014;1(1):e000002.
37. Quint JK, Herrett E, Bhaskaran K, et al. Effect of β blockers on mortality after myocardial infarction in adults with COPD: population based cohort study of UK electronic healthcare records. BMJ. 2013;347:f6650.
38. Vivodtzev I, Tamisier R, Baguet JP, Borel JC, Levy P, Pépin JL. Arterial stiffness in COPD. Chest. 2014;145(4):861-875.
39. Maclay JD, McAllister DA, Johnston S, et al. Increased platelet activation in patients with stable and acute exacerbation of COPD. Thorax. 2011;66(9):769-774.
40. Patel AR, Kowlessar BS, Donaldson GC, et al. Cardiovascular risk, myocardial injury, and exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013;188(9):1091-1099.
41. Donaldson GC, Hurst JR, Smith CJ, Hubbard RB, Wedzicha JA. Increased risk of myocardial infarction and stroke following exacerbation of COPD. Chest. 2010;137(5):1091-1097.
42. Campo G, Pavasini R, Pollina A, Tebaldi M, Ferrari R. On-treatment platelet reactivity in patients with chronic obstructive pulmonary disease undergoing percutaneous coronary intervention. Thorax. 2014;69(1): 80-81.
43. Hole DJ, Watt GC, Davey-Smith G, Hart CL, Gillis CR, Hawthorne VM. Impaired lung function and mortality risk in men and women: findings from the Renfrew and Paisley prospective population study. BMJ. 1996;313(7059):711-715.
44. Mannino DM, Diaz-Guzman E. Interpreting lung function data using 80% predicted and fixed thresholds identifies patients at increased risk of mortality. Chest. 2012;141(1):73-80.
45. Moran AE, Forouzanfar MH, Roth GA, et al. Temporal trends in ischemic heart disease mortality in 21 world regions, 1980 to 2010: the Global Burden of Disease 2010 study. Circulation. 2014;129(14): 1483-1492.
46. Hales CA, Kazemi H. Clinical significance of pulmonary function tests. Pulmonary function after uncomplicated myocardial infarction. Chest. 1977;72(3):350-358.
47. Storey RF, Becker RC, Harrington RA, et al. Pulmonary function in patients with acute coronary syndrome treated with ticagrelor or clopidogrel (from the Platelet Inhibition and Patient Outcomes [PLATO] pulmonary function substudy). Am J Cardiol. 2011;108(11):1542-1546.
48. Vestbo J, Anderson J, Brook RD, et al. The study to understand mortality and morbidity in COPD (SUMMIT) study protocol. Eur Respir J. 2013;41(5):1017-1022.